Study	Reason for exclusion
Blackburn 1981	Allocation: randomly assigned. Participants: people with schizophrenia. Interventions: chlorpromazine, prochlorperazine, perphenazine, promazine, trifluoperazine versus placebo, not chlorpromazine withdrawal.
Bouchard 1998	Allocation: randomly assigned. Participant: people with schizophrenia. Intervention: risperidone versus classical neuroleptics.
Chouinard 1990	Allocation: randomly assigned. Participants: people with schizophrenia. Intervention: remoxipride versus chlorpromazine versus placebo, not chlorpromazine withdrawal.
Crow 1986	Allocation: randomly assigned. Participants: people with first episode of schizophrenia. Interventions: chlorpromazine, fluphenazine, haloperidol, pimozide or trifluoperazine versus placebo, withdrawal study. Outcomes: results not broken down by individual drug.
Diamond 1960	Allocation: randomisation unclear. Participants: people with schizophrenia. Interventions: chlorpromazine versus triflupromazine versus placebo, withdrawal study. Outcomes: results not broken down by individual drug.
Garfield 1966	Allocation: randomly assigned. Participants: people with schizophrenia. Interventions: chlorpromazine, thioridazine, trifluoperazine, perphenazine, prochlorperazine versus placebo, withdrawal study. Outcomes: results not broken down by individual drug.
Goldberg 1967	Allocation: randomly assigned. Participants: people with schizophrenia. Interventions: chlorpromazine versus acetophenazine versus fluphenazine.
Good 1958	Allocation: randomly assigned, cross over design. Participants: people with schizophrenia. Interventions: chlorpromazine versus placebo, withdrawal study. Outcomes: global state, behaviour change (no usable data).
Gross 1960	Allocation: randomly assigned. Participants: people with schizophrenia. Interventions: chlorpromazine, perphenazine, prochlorperazine, promazine, reserpine versus placebo, not chlorpromazine withdrawal.
Hine 1958	Allocation: randomly assigned. Participants: people with schizophrenia. Interventions: chlorpromazine versus placebo, not chlorpromazine withdrawal.
Hogarty 1973 b	Allocation: randomly assigned. Participants: people with schizophrenia. Interventions: chlorpromazine versus placebo, withdrawal study. Outcomes: global state (no usable data).
Howanitz 1996	Allocation: randomly assigned. Participants: people with schizophrenia. Intervention: chlorpromazine versus clozapine.
Knight 1979	Allocation: randomly assigned. Participants: people with schizophrenia. Interventions: thiothixene versus trifluoperazine versus chlorpromazine.
Lapolla 1967	Allocation: randomly assigned. Participant: people with schizophrenia. Intervention: chlorpromazine versus etrafon.
Levine 1997	Allocation: randomly assigned. Participant: people with schizophrenia. Intervention: chlorpromazine, perphenazine versus placebo, not chlorpromazine withdrawal.
Mefferd 1958	Allocation: randomly assigned. Participants: people with schizophrenia. Interventions: chlorpromazine versus placebo. Outcomes: behaviour change (MSRPP), mental state, side effects‐ no usable data.
Melnyk 1966	Allocation: randomly assigned. Participants: people with schizophrenia. Interventions: thioridazine and chlorpromazine versus placebo, withdrawal study. Outcomes: results not broken down by individual drug.
Montero 1971	Allocation: randomisation unclear. Participant: people with schizophrenia. Intervention: chlorpromazine and trifluoperazine versus thioridazine.
Moss 1958	Allocation: not randomised.
Pai 2001	Allocation: randomly assigned. Participant: people with schizophrenia. Intervention: reserpine versus placebo.
Pigache 1993	Allocation: randomly assigned, cross over design. Participants: people with schizophrenia. Interventions: chlorpromazine low dose versus medium dose versus high dose.
Pokorny 1974	Allocation: randomisation unclear. Participant: people with schizophrenia. Intervention: chlorpromazine, trifluoperazine versus thioridazine.
Pollack 1956	Allocation: not randomised.
Prien 1968	Allocation: randomly assigned. Participants: people with schizophrenia. Interventions: chlorpromazine high dose versus chlorpromazine low dose, versus placebo versus drug chosen by physician, not chlorpromazine withdrawal.
Schiele 1961	Allocation: randomisation unclear. Participants: people with schizophrenia. Interventions: chlorpromazine versus thioridazine versus trifluoperazine versus placebo, not chlorpromazine withdrawal.
Slotnick 1971	Allocation: randomisation unclear. Participant: agitated psychiatric patients. Intervention: haloperidol versus chlorpromazine.
Troshinsky 1962	Allocation: randomly assigned. Participant: people with schizophrenia. Interventions: chlorpromazine, trifluoperazine, triflupromazine, thioridazine versus placebo, withdrawal study. Outcomes: results not broken down by individual drug.
Wilson 1982	Allocation: randomly assigned. Participant: people with schizophrenia. Intervention: chlorpromazine versus pimozide.
Wode‐Helgodt 1981	Allocation: not randomised.